## Supplementary Material

Table S1. The genotype distributions (\%) and association of breast cancer risk for rs11638442, rs2073475 and rs16968478.

| SNP | Model | Genotype | Control | Case | OR (95\% CI) ${ }^{\text {a }}$ | $P$-value |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| rs11638442 | Codominant | C/C | 337 (61.7\%) | 316 (59.7\%) | 1 | 0.9 |
|  |  | C/G | 186 (34.1\%) | 188 (35.5\%) | 1.04 (0.80-1.34) |  |
|  |  | G/G | 23 (4.2\%) | 25 (4.7\%) | 1.13 (0.62-2.05) |  |
|  | Dominant | C/C | 337 (61.7\%) | 316 (59.7\%) | 1 | 0.72 |
|  |  | C/G-G/G | 209 (38.3\%) | 213 (40.3\%) | 1.05 (0.82-1.34) |  |
|  | Recessive | C/C-C/G | $523 \text { (95.8\%) }$ | $504 \text { (95.3\%) }$ |  | 0.72 |
|  |  | G/G | $23 \text { (4.2\%) }$ | $25 \text { (4.7\%) }$ | $1.12 \text { (0.62-2.01) }$ |  |
|  | Overdominant | C/C-G/G | 360 (65.9\%) | 341 (64.5\%) | 1 | 0.84 |
|  |  | C/G | 186 (34.1\%) | 188 (35.5\%) | 1.03 (0.80-1.33) |  |
|  | Log-additive | --- | --- | --- | 1.05 (0.85-1.29) | 0.67 |
|  |  | G/G | 180 (33\%) | 162 (30.7\%) | 1 |  |
| rs2073475 | Codominant | G/A | 264 (48.4\%) | 261 (49.5\%) | 1.08 (0.82-1.43) | 0.75 |
|  |  | A/A | 102 (18.7\%) | 104 (19.7\%) | 1.14 (0.80-1.62) |  |
|  | Dominant | G/G | 180 (33\%) | 162 (30.7\%) | 1 | 0.49 |
|  |  | G/A-A/A | 366 (67\%) | 365 (69.3\%) | 1.10 (0.84-1.42) |  |
|  | Recessive | G/G-G/A | 444 (81.3\%) | 423 (80.3\%) | 1 | 0.6 |
|  |  | A/A | 102 (18.7\%) | 104 (19.7\%) | 1.09 (0.80-1.48) |  |
|  | Overdominant | G/G-A/A | 282 (51.6\%) | 266 (50.5\%) |  | 0.82 |
|  |  | G/A | 264 (48.4\%) | 261 (49.5\%) | 1.03 (0.81-1.31) |  |
| rs16968478 | Log-additive | --- | --- | --- | 1.07 (0.90-1.27) | 0.45 |
|  |  | A/A | 163 (29.9\%) | 147 (27.8\%) | 1 |  |
|  | Codominant | G/A | 267 (48.9\%) | 266 (50.3\%) | 1.08 (0.81-1.44) | 0.81 |
|  |  | G/G | 116 (21.2\%) | 116 (21.9\%) | 1.11 (0.79-1.57) |  |
|  | Dominant | A/A | 163 (29.9\%) | 147 (27.8\%) | 1 | 0.53 |
|  |  | G/A-G/G | 383 (70.2\%) | 382 (72.2\%) | 1.09 (0.83-1.43) |  |
|  | Recessive | A/A-G/A | 430 (78.8\%) | 413 (78.1\%) | $1$ | 0.71 |
|  |  | G/G | 116 (21.2\%) | 116 (21.9\%) | 1.06 (0.79-1.42) |  |
|  | Overdominant | A/A-G/G | 279 (51.1\%) | 263 (49.7\%) | 1 | 0.79 |
|  |  | G/A | 267 (48.9\%) | 266 (50.3\%) | 1.03 (0.81-1.32) |  |
|  | Log-additive | --- | --- | --- | 1.06 (0.89-1.25) | 0.53 |

a: $O R(95 \% C I)$ was adjusted for age.

Table S2. The results of Hardy-Weinberg equilibrium (HWE) test for all SNPs.

| SNP | Genotype | Control | $\boldsymbol{P}$-value of HWE | Case | $\boldsymbol{P}$-value of HWE |
| :---: | :---: | :---: | :---: | :---: | :---: |
| rs2959008 | T/T | $205(37.5 \%)$ |  | $229(43.2 \%)$ |  |
|  | C/T | $264(48.4 \%)$ | 0.587 | $239(45.1 \%)$ | 0.976 |
|  | $\mathrm{C} / \mathrm{C}$ | $77(14.1 \%)$ |  | $62(11.7 \%)$ |  |
| rs2959003 | $\mathrm{T} / \mathrm{T}$ | $196(36 \%)$ |  | $218(41.3 \%)$ |  |
|  | $\mathrm{C} / \mathrm{T}$ | $255(46.9 \%)$ | 0.519 | $241(45.6 \%)$ | 0.852 |
|  | $\mathrm{C} / \mathrm{C}$ | $93(17.1 \%)$ |  | $69(13.1 \%)$ |  |
| rs2279357 | $\mathrm{C} / \mathrm{C}$ | $193(35.4 \%)$ |  | $164(30.9 \%)$ |  |
|  | $\mathrm{C} / \mathrm{T}$ | $265(48.6 \%)$ | 0.803 | $253(47.7 \%)$ | 0.403 |
|  | $\mathrm{~T} / \mathrm{T}$ | $87(16 \%)$ |  | $113(21.3 \%)$ |  |
| rs11638442 | $\mathrm{C} / \mathrm{C}$ | $337(61.7 \%)$ |  | $316(59.7 \%)$ |  |
|  | $\mathrm{C} / \mathrm{G}$ | $186(34.1 \%)$ | 0.674 | $188(35.5 \%)$ | 0.660 |
|  | $\mathrm{G} / \mathrm{G}$ | $23(4.2 \%)$ |  | $25(4.7 \%)$ |  |
| rs2073475 | $\mathrm{G} / \mathrm{G}$ | $180(33 \%)$ |  | $162(30.7 \%)$ |  |
|  | G/A | $264(48.4 \%)$ | 0.765 | $261(49.5 \%)$ | 0.951 |
|  | $\mathrm{~A} / \mathrm{A}$ | $102(18.7 \%)$ |  | $104(19.7 \%)$ |  |
| rs16968478 | $\mathrm{A} / \mathrm{A}$ | $163(29.9 \%)$ |  | $147(27.8 \%)$ |  |
|  | G/A | $267(48.9 \%)$ | 0.732 | $266(50.3 \%)$ | 0.834 |
|  | G/G | $116(21.2 \%)$ |  | $116(21.9 \%)$ |  |

© 2012 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).

